Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03568461 · OUTCOME

Summary of Exposure of CD3+ Tisagenlecleucel Cells in Peripheral Blood for Tmax

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma · Source last updated 2026-07-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
Full Range
Time frame
From pre-dose until 60 months after infusion

What was measured

In vivo cellular kinetics of CD3+/CTL019+ levels tisagenlecleucel cells detected by flow cytometry base on best overall response (BOR). The cellular kinetic parameters were estimated from the percentages of CD3+/CTL019+ cells obtained from flow cytometry. Flow cytometry measures the surface expression of chimeric antigen receptors (CARs) on T cells.

Analysis population: Cellular Kinetic Analysis Set (CKAS) consisted of participants in the interim efficacy analysis set (IEAS) or efficacy analysis set (EAS) (at time of the interim and primary analysis respectively) who provided an evaluable cellular kinetic profile (at least one cellular kinetic parameter).

Groups in this outcome

CTL019

All participants who were enrolled in the study

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
CTL01978

Reported measurements

Source class 1
Values in days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
CTL0198.86Not reported1.8728.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.87
        upper Limit
        28.0
        value
        8.86
denoms
  1. counts
    1. group Id
      OG000
      value
      78
    units
    Participants
description
In vivo cellular kinetics of CD3+/CTL019+ levels tisagenlecleucel cells detected by flow cytometry base on best overall response (BOR). The cellular kinetic parameters were estimated from the percentages of CD3+/CTL019+ cells obtained from flow cytometry. Flow cytometry measures the surface expression of chimeric antigen receptors (CARs) on T cells.
dispersion Type
Full Range
groups
  1. description
    All participants who were enrolled in the study
    id
    OG000
    title
    CTL019
param Type
MEDIAN
population Description
Cellular Kinetic Analysis Set (CKAS) consisted of participants in the interim efficacy analysis set (IEAS) or efficacy analysis set (EAS) (at time of the interim and primary analysis respectively) who provided an evaluable cellular kinetic profile (at least one cellular kinetic parameter).
reporting Status
POSTED
time Frame
From pre-dose until 60 months after infusion
title
Summary of Exposure of CD3+ Tisagenlecleucel Cells in Peripheral Blood for Tmax
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice